Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients.

Biochemical genetics - 1 Aug 2016

Repnik Katja, Koder Silvo, Skok Pavel, Ferkolj Ivan, Potočnik Uroš

Abstract excerpt

Tumor necrosis factor α inhibitors (anti-TNF) have improved treatment of several complex diseases, including Crohn's disease (CD). However, the effect varies and approximately one-third of the patients do not respond. Since blood parameters as well as genetic factors have shown a great potential to predict response during treatment, the aim of the study was to evaluate response to anti-TNF treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation

Share to Genetic Markers

Share to Hemochromatosis Protein

Share to Slovenia

Share to Transferrin

Share to Treatment Outcome

Source

Identifiers

PMID: 27115882
DOI: 10.1007/s10528-016-9734-0

Genes

HFE
TNF
ADA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients.PMID 27115882Read ↗

A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability.Semantic proximity Read ↗

The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.Semantic proximity Read ↗

Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients.Semantic proximity Read ↗

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read ↗

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.Semantic proximity Read ↗

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Semantic proximity Read ↗

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.Semantic proximity Read ↗

Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s diseaseSemantic proximity Read ↗

Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn’s diseaseSemantic proximity Read ↗

Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.